Vildagliptin: A novel oral therapy for type 2 diabetes mellitus
- 15 June 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 64 (12) , 1265-1273
Abstract
Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed.Keywords
This publication has 27 references indexed in Scilit:
- Dispelling Myths and Removing Barriers About Insulin in Type 2 DiabetesThe Diabetes Educator, 2006
- Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile)Biochemical Pharmacology, 2005
- Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes MellitusTreatments in Endocrinology, 2005
- Overview of Incretin HormonesHormone and Metabolic Research, 2004
- Incretins, insulin secretion and Type 2 diabetes mellitusDiabetologia, 2004
- 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic PropertiesJournal of Medicinal Chemistry, 2003
- Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group studyThe Lancet, 2002
- Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic PatientsThe Journal of Clinical Endocrinology & Metabolism, 2001
- Effect of Nutrient Ingestion on Glucagon-Like Peptide 1 (7-36 Amide) Secretion in Human Type 1 and Type 2 DiabetesHormone and Metabolic Research, 2000
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Journal of Clinical Investigation, 1993